Kornimate/medical-research-clean huggingface dataset:
abatacept in the treatment and prevention of active systemic lupus erythematosus (sle) flares in combination with prednisone

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this clinical research study is to learn whether abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). all participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. the safety of this treatment will also be studied.


Eligibility criteria:
inclusion criteria: * participants must be diagnosed with sle and be experiencing an active lupus flare in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a screening visit (arthritis) * stable dose of prednisone (\<30mg) for at least one month exclusion criteria: * participants experiencing an active lupus flare in the kidney or central nervous systems * treatment with a stable dose of azathioprine, mycophenolate mofetil, hydroxychloroquine, chloroquine, or methotrexate for less than three months prior to the study * participants with active viral or bacterial infections * participants with any other autoimmune disease as a main diagnosis * prior treatment with rituximab

Keywords: sle
satisfaction survey for amyotrophic lateral sclerosis (als) patients comparing rooms with and without assistive technology

Conditions: Amyotrophic Lateral Sclerosis; Neurodegenerative Disease; Motor Neuron Disease

Summary: the purpose of this study is : 1. to assess the als patient's satisfaction related to a hospital stay on the neurology floor of hahnemann hospital. 2. to compare the reported satisfaction of those individuals who stayed in a standard hospital room with those who stayed in room 1455. room 1455 is a room specifically set up with assistive technology related to environmental controls for individuals with disabilities. 3. to look at frequency of use of the various pieces of adaptive equipment.


Eligibility criteria:
inclusion criteria: * in-patients with probable or definite als, ages 18 - 90, staying on the neurology floor of hahnemann hospital exclusion criteria: * in-patients who do not meet the criteria of the diagnosis of als.

Keywords: amyotrophic lateral sclerosis cerebrospinal fluid neurodegenerative disease motor neuron disease autonomic nervous system neurodegenerative diseases movement disorders quality of life
capturing parkinson's disease medication side effects during daily activities

Conditions: Parkinson's Disease; Dyskinesia

Summary: the purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with parkinson disease (pd) independent of voluntary activity being performed and other pd motor symptoms (e.g. tremor).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of probable or definite idiopathic parkinson disease with motor fluctuations that include dyskinesias after taking their usual dose of levodopa/carbidopa exclusion criteria: * antipsychotic medications (including quetiapine and clozapine) * coexisting neurologic disease such as stroke or dementia * lacking capacity for informed consent * residing in a nursing home * comorbid non-neurologic illnesses that impacts the ability to perform the study tasks * implantable defibrillators

Keywords: levodopa tremor bradykinesia motion sensors
prevention of complications of eye surgery

Conditions: Strabismus

Summary: this study was designed to investigate pre-operatively measured parameters of various anaesthetic regimes, iris color, sex, age, surgical time, severity of marcus-gunn pupil (mgp), type of mechanical stimulation of eye, and number of extraocular muscle (eom) under tension as predictors of significant ocr in pediatric strabismus surgery.

objectives: despite various proposed maneuver, successfully predicting an oculocardiac reflex (ocr) is difficult to achieve. this study was designed to investigate pre-operatively measured parameters of various anaesthetic regimes, iris color, sex, age, surgical time, severity of marcus-gunn pupil (mgp), type of mechanical stimulation of eye, and number of extraocular muscle (eom) under tension as predictors of significant ocr in pediatric strabismus surgery. methods: three hundred patients were randomized to one of three anesthetic regimes: group p: propofol (2 mg/kg), alfentanil 0.02 mg/kg, and atracurium 0.5 mg/kg at induction; group k: ketamine (2mg/kg), alfentanil 0.02 mg/kg, and atracurium 0.5 mg/kg at induction; group t: thiopental (5mg/kg), alfentanil 0.02 mg/kg, and atracurium 0.5 mg/kg at induction. ocr was defined as a 10% change in heart rate induced by traction. results: incidence of ocr was significantly lower in patients in group k compared with patients in group t or p. chi-square test results showed that the occurrence of ocr was significantly associated with difference of iris color (p=0.01). the occurrence of the ocr did not correlate with sex, age, duration of surgery, iris color, severity of mgp, number of eom under tension, and type of mechanical stimulation of eye. type of mechanical stimulation of eye or number of eom under tension increased risk of developing ocr by 0.81 (95% ci, 0.66-0.98) and 1.29 (95% ci; 1.12-1.63) respectively. conclusions: induction of anesthesia with ketamine is associated with least hemodynamic changes induced by ocr during strabismus surgery. the prediction of oculocardiac reflex propensity remains elusive.

Eligibility criteria:
inclusion criteria: * 300 asa physical status i or ii patients, aged 2-18 years, who candidate for elective strabismus surgery exclusion criteria: * trauma to eye, asa iii or iv, who had contraindication for using thiopental, ketamine, or propofol, had cardiovascular diseases or had taken cardiovascular drugs

Keywords: oculocardiac reflex; strabismus surgery;
vanos cream and skin barrier function

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine the effect of short-term therapy using "vanos cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. this cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. this cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.


Eligibility criteria:
inclusion criteria: * diagnosis of ad according to hanifin-rajka criteria (see appendix b) * age 12 years or older * must have an investigator's global assessment (iga) score of moderate, severe, or very severe (see appendix c) * must have failed to achieve adequate disease despite adequate topical or systemic therapy * must be a candidate, according to the principal investigator and standard of care, for a super-potent topical steroid course. subjects that are candidates for super-potent topical steroids are defined as subjects whose disease is not adequately controlled with medium-potency topical steroids or systemic therapy, including phototherapy. exclusion criteria: * active skin infection * hypersensitivity to any ingredients in vanos cream * previous use of super-potent topical steroids within 2 weeks of starting study (class i steroid).

Keywords: skin barrier atopic dermatitis corticosteroid effects on skin severity and barrier function
a weight loss rct comparing keyto vs weight watchers

Conditions: Overweight and Obesity; Ketogenic Diet

Summary: very low-carbohydrate ketogenic diet may have beneficial metabolic and weight loss effects, however, adhering to this diet may be challenging. keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote dietary change and weight loss. the purpose of this research is to test the keyto self-monitoring + app intervention against a "standard of care" weight loss dietary app (weight watchers). 144 participants will be recruited through facebook ads, provide online consent, and will be randomized to one of the two conditions. weight loss after 12 weeks will be assessed as the primary outcome, with weight loss at 24 and 48 weeks being secondary outcomes. blood samples will be collected at baseline and 12 weeks with optional blood samples at 48 weeks follow up.


Eligibility criteria:
inclusion criteria: * age 18-64 * living in the state of california * body mass index (bmi) 27-43 * must speak, read, and comprehend english * access to reliable internet and wi-fi * must have a valid email address and phone number * must have an apple iphone (iphone 7 or later, ios 11 or later) with cellular data plan * must have a kitchen and be willing to cook * willingness to reduce carbohydrate intake to less than 30g/day * willingness to restrict intake of added sugar, bread, grain, rice, pasta, sweets, most fruits, pastries, and other carbohydrates * willingness to comply with a strict diet for 12 months * willingness to eat a diet that is primarily plant and fish-based * interest in losing weight exclusion criteria: * hiv or immunocompromised * current or past cancer diagnosis * pregnant, breastfeeding, or planned pregnancy in next 12 months * beginning or ending hormonal contraception in next 12 months * current diagnosis of diabetes * history of heart attack or stent * currently taking glucose-lowering drugs, statins, or oral steroids * history of gastric bypass surgery or any other weight-loss surgery * history of anorexia or bulimia * history of mental illness * current smoker or smoked cigarettes within past 12 months * currently eating fewer than 50 g carbohydrates per day * have tried a low-carb, high fat (ketogenic diet) within the past 3 months * recent weight loss or gain of more than 5% body weight in past 6 months * previous experience with the weight watchers diet app * experience with a low-carbohydrate of ketogenic diet within past 6 months

Keywords: diet weight loss ketogenic diet low carbohydrate
myocardial ischemia and transfusion

Conditions: Myocardial Infarction; Anemia

Summary: the purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic.

in most clinical settings, evidence suggests it is safe to wait to give a blood transfusion. however, for those who have suffered a heart attack, there is a lack of high quality evidence to guide transfusions. this 3500 subject multi-center randomized trial will fill that void. hospital inpatients diagnosed with myocardial infarction who have blood counts less than 10 g/dl are randomized to receive either a liberal or a restrictive transfusion strategy. patients randomized to the liberal transfusion strategy will receive a red blood cell transfusion anytime there is a blood count of less than 10 g/dl. patients randomized to the restrictive transfusion strategy are permitted to receive a blood transfusion if the blood count is below 8 g/dl and the physician believes it is in the patient's best interest. a transfusion will be strongly recommended if the blood count drops to less than 7 g/dl. if the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion is ordered regardless of the blood count. the transfusions strategies will be maintained until hospital discharge for a maximum of 30 days. patients will be followed for 30 days for clinically relevant outcomes. vital status will be confirmed at 180 days.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * either st segment elevation myocardial infarction or non st segment elevation myocardial infarction consistent with the 3rd universal definition of myocardial infarction criteria that occurs on admission or during the index hospitalization * hemoglobin concentration less than 10 g/dl at the time of random allocation * patient physician believes that both of the transfusion strategies are consistent with good medical care for the patient exclusion criteria: * uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood * decline blood transfusion * scheduled for cardiac surgery during the current admission * receiving only palliative treatment * known that follow-up will not be possible at 30 days * previously participated in mint * currently enrolled in a competing study that interferes with the intervention or follow-up of mint or enrolled in a competing study that has not been approved by the local institutional review board * patient physician does not believe the patient is an appropriate candidate for the trial

Keywords: red blood cell transfusion anemia heart disease cardiovascular disease
precision transcranial magnetic stimulation for depression based on orbital frontal cortex-habenula circuitry

Conditions: Depression; Transcranial Magnetic Stimulation

Summary: thirty depressed patients will be recruited to select individualized transcranial magnetic stimulation targets based on individual orbital frontal cortex and habenula functional activity connectivity for 10 or 20 treatments to assess the efficacy and safety of this intervention


Eligibility criteria:
inclusion criteria: * gender is not limited, age 18～60 years old; * comply with the diagnostic criteria for major depressive disorder in the diagnostic and statistical manual of mental disorders-fifth edition (dsm-5) of the united states of america; * hamilton rating scale for depression (hamd) 17-item score ≥ 18; * the medication/psychotherapy received by the subject prior to the start of the study remained stable for at least 4 weeks . exclusion criteria: * history of serious somatic diseases or diseases that may affect the central nervous system (e.g., tumors, syphilis, etc.); * neurological disorders or risk of seizures, such as previous craniosynostosis, head trauma, alcoholism, abnormal electroencephalograms, mri evidence of structural abnormalities in the brain, or family history of epilepsy; * patients with bipolar disorder and depression due to other psychiatric disorders (e.g., psychoactive and non-dependent substances); * contraindications to mri scanning or transcranial magnetic stimulation therapy, such as metal or electronic devices placed in the body (intracranial metal foreign bodies, cochlear implants, pacemakers and stents and other metal foreign bodies), space phobia; * people with psychotic symptoms requiring joint application of antipsychotic drugs; * those with high risk of suicide, or those who have already committed suicide or serious self-injury behavior requiring urgent intervention; * those who are pregnant, breastfeeding or planning to become pregnant during the trial; * other conditions judged by the investigator to be unsuitable as research subjects.
the efficacy and safety of atorva® 20mg versus lipitor® 20mg

Conditions: Hypercholesterolemia

Summary: the generic formulation of atorvastatin (atorva®) 20mg was not inferior to the branded formulation of atorvastatin (lipitor®) 20mg in this 8-week treatment of hyperlipidemic korean patients. in pp analysis, the ldl cholesterol goal achievement rate was significantly higher in atorva group. both treatments were well tolerated.


Eligibility criteria:
inclusion criteria: * eligible patients were men or women aged between 20 and 79 years who have not achieved ldl cholesterol goals using the national cholesterol education program adult treatment panel ⅲ (ncep-atp ⅲ) guideline, with the treatment goal of ldl cholesterol being \<100 mg/dl for patients with coronary artery disease (cad) or cad-equivalent disease, \<130 mg/dl for patients with multiple risk factors (10-year coronary heart disease \[chd\] risk ≤20%), and \<160 mg/dl for patients with 0 to 1 risk factors. exclusion criteria: * exclusion criteria were as follows: currently taking any kind of anti-hyperlipidemic drug (within 4 weeks before enrollment); hypersensitivity or intolerance to atorvastatin or other hmg-coa reductase inhibitor; newly diagnosed (within 3 months before enrollment) or uncontrolled diabetes (hemoglobin a1c \>9%); uncontrolled hypertension (systolic blood pressure \>160 mmhg or diastolic blood pressure \>100 mmhg); hepatic dysfunction (alanine aminotransferase \[alt\] or aspartate aminotransferase \[ast\] levels ≥2 times the upper limit of normal \[uln\]); an unexplained serum creatinine kinase (ck) elevation \>2 times the uln, chronic renal failure (a serum creatinine concentration \>2.5 mg/dl); in patients who experienced operation at the time of screening, the patients must have a result of lipid profiles within 24 hours or after 6 weeks; a history of malignancy or cervical dysplasia; pregnant or breastfeeding women; women of childbearing potential had to be using adequate methods of contraception; a history of drug abuse or alcoholism; participation in other studies 4 weeks before enrollment. patients could also be excluded if their participation was considered inappropriate by the study physician.

Keywords: atorva generic atorvastatin hypercholesterolemia
topical ganciclovir versus systemic aciclovir in the treatment of herpetic keratitis

Conditions: Herpetic Keratitis

Summary: traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of hsv. topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. this study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition


Eligibility criteria:
inclusion criteria: * patients diagnosed with herpetic keratitis exclusion criteria: * patients with known allergies to ganciclovir or acyclovir * severe ocular surface disease * those who have previously received antiviral therapy for herpetic keratitis within the last month

Keywords: acyclovir ganciclovir
a cardiac surgery virtual nutrition intervention program feasibility study-vip study protocol

Conditions: Nutritional Deficiency

Summary: this feasibility study will look to identify the impact that a remote/virtual nutritional intervention can have on nutrition literacy and knowledge retention of the cardiac surgery patient.

the proposed vip study will utilize an interventional feasibility design to implement and evaluate the impact of a virtual nutrition intervention prehab program on cardiac surgery patients. the vip study looks to measure patient adherence and acceptability, and practicality of the remote platform in hopes it will illicit change to the current standard of nutrition care being provided to cardiac surgery patients. the current standards of care do not call for dietitian involvement for cardiac surgery patients' pre-surgery and little to no involvement for patients not receiving cabg surgery. this feasibility study looks to address this gap in current patient nutrition care. the study intervention will provide eligible patients (n=20) with access to four 25-30 minute virtual sessions with a registered dietitian during the two-week period prior to surgery. the dietitian will provide the patient with nutrition counseling prior to the patient's elective cardiac surgery. zoom (or equivalent) software will be utilized as a remote platform to connect the dietitian virtually with participants during all sessions. the four sessions will follow the same presentation format and will provide all participants with identical nutrition education with curriculum content progressing in each subsequent session. each session will be comprised of protein education and goal setting, with education content building on previous sessions with a goal of improving patient protein intake perioperatively. data will be collected on: (1) participant demographics, (2) physical function, (3) nutritional status and (4) nutrition literacy.

Eligibility criteria:
inclusion criteria: * 18 years or older * undergoing non-emergent/elective cardiac surgery exclusion criteria: * not able to communicate in english (read or write) * in-patients (urgent or emergent care) * patients who self report protein supplementation on a regular basis
efficacy and safety study of rosiglitazone/metformin therapy vs rosiglitazone and metformin in type 2 diabetes subjects

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. the primary objective of the study is to demonstrate superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.


Eligibility criteria:
inclusion criteria: * 18 to 70 years of age * clinical diagnosis of type 2 diabetes * hba1c \>7.5% to 11% * fpg \<270mg/dl (15mmol) * current treatment with diet and/or exercise alone, or no more than 15 days of an anti-diabetic medication or insulin within 12 weeks of screening exclusion criteria: * clinically significant renal or hepatic disease * presence of anemia * presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring therapy * systolic blood pressure \>170mmhg or diastolic blood pressure \>100mmhg, while on anti-hypertensive treatment * chronic disease requiring intermittent or chronic treatment with corticosteroids * any female lactating, pregnant, or planning to become pregnant * history of hepatocellular reaction, severe edema or a medically serious fluid related event associated with any thiazolidinedione * presence of acute or chronic metabolic acidosis * history of diabetic ketoacidosis

Keywords: hba1c drug-naive type 2 diabetes
trial of svtampons vs glass vaginal dilators in treatment of vaginismus

Conditions: Vaginismus

Summary: the aim of this study is to compare the success rates of vaginismus therapy using a tampon or a dilator during exposure

tampon group exercises will be performed with tampon dilator group exercises wil be performed with dilator

Eligibility criteria:
inclusion criteria: * non-pregnant/non lactating women aged between 18-50 * diagnosed with primary vaginismus of lamont level ii or higher exclusion criteria: * hymenal abnormalities, congenital vaginal abnormalities, vulvodynia, secondary vaginismus following physical or psychological trauma, infection, menopausal period or pelvic pathology and with any psychiatric or physiological disease. * patients with husbands possessing a history of sexual dysfunction (erectile dysfunction or premature ejaculation, for example)

Keywords: genitopelvic pain disorder, vaginismus